Hepatitis C : diagnosis, anti-viral therapy, after-care. Hungarian consensus guideline
Approximately 70,000 people are infected with hepatitis C virus in Hungary, and more than half of them are not aware of their infection. From the point of infected individuals early recognition and effective treatment of related liver injury may prevent consequent advanced liver diseases and complications (liver cirrhosis, liver failure and liver cancer) and can increase work productivity and life expectancy. Furthermore, these could from prevent further spread of the virus as well as reduce substantially long term financial burden of related morbidity, as a socioeconomic aspect. Pegylated interferon + ribavirin dual therapy, which is available in Hungary since 2003, can clear the virus in 40-45% of previously not treated (naïve), and in 5-21% of previous treatment-failure patients. Addition of a direct acting first generation protease inhibitor drug (boceprevir or telaprevir) to the dual therapy increases the chance of sustained viral response to 63-75% and 59-66%, respectively. These two protease inhibitors are available and financed for a segment of Hungarian patients since May 2013. Between 2013 and February 2015, other direct acting antivirals and interferon-free combination therapies have been registered for the treatment of chronic hepatitis C with a potential efficacy over 90% and typically with a short duration of 8-12 weeks. Indication of therapy includes exclusion of contraindications to the drugs and demonstration of viral replication with consequent liver injury, i.e., inflammation and/or fibrosis in the liver. Non-invasive methods (elastography and biochemical methods) are accepted and preferred for staging liver damage (fibrosis). For initiation of treatment accurate and timely molecular biology tests are mandatory. Eligibility for treatment is a subject of individual central medical review. Due to budget limitations therapy is covered only for a proportion of patients by the National Health Insurance Fund. Priority is given to those with urgent need based on a Hungarian Priority Index system reflecting primarily the stage of liver disease, and considering also additional factors, i.e., activity and progression of liver disease, predictive factors of treatment and other special issues. Approved treatments are restricted to the most cost-effective combinations based on the cost per sustained viral response value in different patient categories with consensus between professional organizations, National Health Insurance Fund and patient organizations. More expensive therapies might be available upon co-financing by the patient or a third party. Interferon-free treatments and shorter therapy durations preferred as much as financially feasible. A separate budget is allocated to cover interferon-free treatments for the most-in-need interferon ineligible/intolerant patients, and for those who have no more interferon-based therapy option.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:156 |
|---|---|
| Enthalten in: |
Orvosi hetilap - 156(2015), 9 vom: 01. März, Seite 343-51 |
| Sprache: |
Ungarisch |
|---|
| Weiterer Titel: |
Hepatitis C-vírus-fertőzés: diagnosztika, antivirális terápia, kezelés utáni gondozás. Magyar konszenzusajánlás |
|---|
| Beteiligte Personen: |
Hunyady, Béla [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.05.2015 Date Revised 02.12.2018 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1556/OH.2015.30106 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM246433469 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM246433469 | ||
| 003 | DE-627 | ||
| 005 | 20231224143044.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||hun c | ||
| 024 | 7 | |a 10.1556/OH.2015.30106 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0821.xml |
| 035 | |a (DE-627)NLM246433469 | ||
| 035 | |a (NLM)25702254 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a hun | ||
| 100 | 1 | |a Hunyady, Béla |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hepatitis C |b diagnosis, anti-viral therapy, after-care. Hungarian consensus guideline |
| 246 | 3 | 3 | |a Hepatitis C-vírus-fertőzés: diagnosztika, antivirális terápia, kezelés utáni gondozás. Magyar konszenzusajánlás |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.05.2015 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Approximately 70,000 people are infected with hepatitis C virus in Hungary, and more than half of them are not aware of their infection. From the point of infected individuals early recognition and effective treatment of related liver injury may prevent consequent advanced liver diseases and complications (liver cirrhosis, liver failure and liver cancer) and can increase work productivity and life expectancy. Furthermore, these could from prevent further spread of the virus as well as reduce substantially long term financial burden of related morbidity, as a socioeconomic aspect. Pegylated interferon + ribavirin dual therapy, which is available in Hungary since 2003, can clear the virus in 40-45% of previously not treated (naïve), and in 5-21% of previous treatment-failure patients. Addition of a direct acting first generation protease inhibitor drug (boceprevir or telaprevir) to the dual therapy increases the chance of sustained viral response to 63-75% and 59-66%, respectively. These two protease inhibitors are available and financed for a segment of Hungarian patients since May 2013. Between 2013 and February 2015, other direct acting antivirals and interferon-free combination therapies have been registered for the treatment of chronic hepatitis C with a potential efficacy over 90% and typically with a short duration of 8-12 weeks. Indication of therapy includes exclusion of contraindications to the drugs and demonstration of viral replication with consequent liver injury, i.e., inflammation and/or fibrosis in the liver. Non-invasive methods (elastography and biochemical methods) are accepted and preferred for staging liver damage (fibrosis). For initiation of treatment accurate and timely molecular biology tests are mandatory. Eligibility for treatment is a subject of individual central medical review. Due to budget limitations therapy is covered only for a proportion of patients by the National Health Insurance Fund. Priority is given to those with urgent need based on a Hungarian Priority Index system reflecting primarily the stage of liver disease, and considering also additional factors, i.e., activity and progression of liver disease, predictive factors of treatment and other special issues. Approved treatments are restricted to the most cost-effective combinations based on the cost per sustained viral response value in different patient categories with consensus between professional organizations, National Health Insurance Fund and patient organizations. More expensive therapies might be available upon co-financing by the patient or a third party. Interferon-free treatments and shorter therapy durations preferred as much as financially feasible. A separate budget is allocated to cover interferon-free treatments for the most-in-need interferon ineligible/intolerant patients, and for those who have no more interferon-based therapy option | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a asunaprevir | |
| 650 | 4 | |a boceprevir | |
| 650 | 4 | |a daclatasvir | |
| 650 | 4 | |a dasabuvir | |
| 650 | 4 | |a direct acting antiviral drug | |
| 650 | 4 | |a direkt ható antivirális szer | |
| 650 | 4 | |a genotype | |
| 650 | 4 | |a genotípus | |
| 650 | 4 | |a hepatitis C virus | |
| 650 | 4 | |a hepatitis C-vírus | |
| 650 | 4 | |a hepatocellular cancer | |
| 650 | 4 | |a interferon | |
| 650 | 4 | |a ledipasvir | |
| 650 | 4 | |a liver cirrhosis | |
| 650 | 4 | |a májrák | |
| 650 | 4 | |a májzsugor | |
| 650 | 4 | |a ombitasvir | |
| 650 | 4 | |a paritaprevir | |
| 650 | 4 | |a pegilált interferon | |
| 650 | 4 | |a pegylated interferon | |
| 650 | 4 | |a polimerase-inhibitor | |
| 650 | 4 | |a polimerázgátló | |
| 650 | 4 | |a protease-inhibitor | |
| 650 | 4 | |a proteázgátló | |
| 650 | 4 | |a ribavirin | |
| 650 | 4 | |a ritonavir | |
| 650 | 4 | |a simeprevir | |
| 650 | 4 | |a sofosbuvir | |
| 650 | 4 | |a telaprevir | |
| 650 | 4 | |a viral hepatitis | |
| 650 | 4 | |a vírushepatitis | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Interferon alpha-2 |2 NLM | |
| 650 | 7 | |a Interferon-alpha |2 NLM | |
| 650 | 7 | |a Oligopeptides |2 NLM | |
| 650 | 7 | |a Protease Inhibitors |2 NLM | |
| 650 | 7 | |a Recombinant Proteins |2 NLM | |
| 650 | 7 | |a Polyethylene Glycols |2 NLM | |
| 650 | 7 | |a 3WJQ0SDW1A |2 NLM | |
| 650 | 7 | |a Ribavirin |2 NLM | |
| 650 | 7 | |a 49717AWG6K |2 NLM | |
| 650 | 7 | |a telaprevir |2 NLM | |
| 650 | 7 | |a 655M5O3W0U |2 NLM | |
| 650 | 7 | |a N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide |2 NLM | |
| 650 | 7 | |a 89BT58KELH |2 NLM | |
| 650 | 7 | |a Proline |2 NLM | |
| 650 | 7 | |a 9DLQ4CIU6V |2 NLM | |
| 650 | 7 | |a peginterferon alfa-2b |2 NLM | |
| 650 | 7 | |a G8RGG88B68 |2 NLM | |
| 650 | 7 | |a peginterferon alfa-2a |2 NLM | |
| 650 | 7 | |a Q46947FE7K |2 NLM | |
| 700 | 1 | |a Gerlei, Zsuzsanna |e verfasserin |4 aut | |
| 700 | 1 | |a Gervain, Judit |e verfasserin |4 aut | |
| 700 | 1 | |a Horváth, Gábor |e verfasserin |4 aut | |
| 700 | 1 | |a Lengyel, Gabriella |e verfasserin |4 aut | |
| 700 | 1 | |a Pár, Alajos |e verfasserin |4 aut | |
| 700 | 1 | |a Rókusz, László |e verfasserin |4 aut | |
| 700 | 1 | |a Szalay, Ferenc |e verfasserin |4 aut | |
| 700 | 1 | |a Telegdy, László |e verfasserin |4 aut | |
| 700 | 1 | |a Tornai, István |e verfasserin |4 aut | |
| 700 | 1 | |a Werling, Klára |e verfasserin |4 aut | |
| 700 | 1 | |a Makara, Mihály |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Orvosi hetilap |d 1949 |g 156(2015), 9 vom: 01. März, Seite 343-51 |w (DE-627)NLM000021601 |x 1788-6120 |7 nnns |
| 773 | 1 | 8 | |g volume:156 |g year:2015 |g number:9 |g day:01 |g month:03 |g pages:343-51 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1556/OH.2015.30106 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 156 |j 2015 |e 9 |b 01 |c 03 |h 343-51 | ||